EGFR and colorectal cancer: Over 1.8 million new colorectal cancer (CRC) cases were estimated to occur in 2018 worldwide.1 Colorectal cancer ranks third in global incidence but second in mortality, claiming 90,000 lives yearly.1 The treatment of patients with advanced metastatic colorectal cancer (mCRC) includes oxaliplatin and irinotecan-containing chemotherapy, and patients with RAS wild-type tumours should also receive anti-EGFR antibodies (e.g. cetuximab or panitumumab).2 New drugs have been developed in recent years for patients who are refractory to these agents.